| Literature DB >> 33466447 |
Valentina Condelli1, Giovanni Calice1, Alessandra Cassano2, Michele Basso2, Maria Grazia Rodriquenz3, Angela Zupa4, Francesca Maddalena1, Fabiana Crispo1, Michele Pietrafesa1, Michele Aieta3, Alessandro Sgambato1, Giampaolo Tortora2, Pietro Zoppoli1, Matteo Landriscina1,5.
Abstract
Epigenetics is involved in tumor progression and drug resistance in human colorectal carcinoma (CRC). This study addressed the hypothesis that the DNA methylation profiling may predict the clinical behavior of metastatic CRCs (mCRCs). The global methylation profile of two human mCRC subgroups with significantly different outcome was analyzed and compared with gene expression and methylation data from The Cancer Genome Atlas COlon ADenocarcinoma (TCGA COAD) and the NCBI GENE expression Omnibus repository (GEO) GSE48684 mCRCs datasets to identify a prognostic signature of functionally methylated genes. A novel epigenetic signature of eight hypermethylated genes was characterized that was able to identify mCRCs with poor prognosis, which had a CpG-island methylator phenotype (CIMP)-high and microsatellite instability (MSI)-like phenotype. Interestingly, methylation events were enriched in genes located on the q-arm of chromosomes 13 and 20, two chromosomal regions with gain/loss alterations associated with adenoma-to-carcinoma progression. Finally, the expression of the eight-genes signature and MSI-enriching genes was confirmed in oxaliplatin- and irinotecan-resistant CRC cell lines. These data reveal that the hypermethylation of specific genes may provide prognostic information that is able to identify a subgroup of mCRCs with poor prognosis.Entities:
Keywords: CIMP status; MSI-like signature; colorectal carcinoma; gene signature; prognosis; promoter methylation
Year: 2021 PMID: 33466447 PMCID: PMC7796477 DOI: 10.3390/cancers13010158
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639